These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 1855219

  • 1. Phase I immunotoxin trial in patients with B-cell lymphoma.
    Vitetta ES, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D.
    Cancer Res; 1991 Aug 01; 51(15):4052-8. PubMed ID: 1855219
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of an anti-CD19 deglycosylated ricin A chain immunotoxin in non-Hodgkin's lymphoma: effect of an intensive schedule of administration.
    Conry RM, Khazaeli MB, Saleh MN, Ghetie V, Vitetta ES, Liu T, LoBuglio AF.
    J Immunother Emphasis Tumor Immunol; 1995 Nov 01; 18(4):231-41. PubMed ID: 8680651
    [Abstract] [Full Text] [Related]

  • 3. A Phase I study with an anti-CD30 ricin A-chain immunotoxin (Ki-4.dgA) in patients with refractory CD30+ Hodgkin's and non-Hodgkin's lymphoma.
    Schnell R, Staak O, Borchmann P, Schwartz C, Matthey B, Hansen H, Schindler J, Ghetie V, Vitetta ES, Diehl V, Engert A.
    Clin Cancer Res; 2002 Jun 01; 8(6):1779-86. PubMed ID: 12060617
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19(+), CD22(+) B cell lymphoma.
    Messmann RA, Vitetta ES, Headlee D, Senderowicz AM, Figg WD, Schindler J, Michiel DF, Creekmore S, Steinberg SM, Kohler D, Jaffe ES, Stetler-Stevenson M, Chen H, Ghetie V, Sausville EA.
    Clin Cancer Res; 2000 Apr 01; 6(4):1302-13. PubMed ID: 10778955
    [Abstract] [Full Text] [Related]

  • 5. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma.
    Multani PS, O'Day S, Nadler LM, Grossbard ML.
    Clin Cancer Res; 1998 Nov 01; 4(11):2599-604. PubMed ID: 9829722
    [Abstract] [Full Text] [Related]

  • 6. A Phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-Hodgkin's lymphoma.
    Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM.
    Clin Cancer Res; 1999 Sep 01; 5(9):2392-8. PubMed ID: 10499609
    [Abstract] [Full Text] [Related]

  • 7. Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.
    Byers VS, Rodvien R, Grant K, Durrant LG, Hudson KH, Baldwin RW, Scannon PJ.
    Cancer Res; 1989 Nov 01; 49(21):6153-60. PubMed ID: 2790828
    [Abstract] [Full Text] [Related]

  • 8. A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy.
    Amlot PL, Stone MJ, Cunningham D, Fay J, Newman J, Collins R, May R, McCarthy M, Richardson J, Ghetie V.
    Blood; 1993 Nov 01; 82(9):2624-33. PubMed ID: 8219217
    [Abstract] [Full Text] [Related]

  • 9. In vivo therapy of the BCL1 tumor: effect of immunotoxin valency and deglycosylation of the ricin A chain.
    Fulton RJ, Uhr JW, Vitetta ES.
    Cancer Res; 1988 May 01; 48(9):2626-31. PubMed ID: 3258547
    [Abstract] [Full Text] [Related]

  • 10. Antitumor activity of Fab' and IgG-anti-CD22 immunotoxins in disseminated human B lymphoma grown in mice with severe combined immunodeficiency disease: effect on tumor cells in extranodal sites.
    Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, Vitetta ES.
    Cancer Res; 1991 Nov 01; 51(21):5876-80. PubMed ID: 1933855
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of ricin A chain-containing immunotoxins directed against CD19 and CD22 antigens on normal and malignant human B-cells as potential reagents for in vivo therapy.
    Ghetie MA, May RD, Till M, Uhr JW, Ghetie V, Knowles PP, Relf M, Brown A, Wallace PM, Janossy G.
    Cancer Res; 1988 May 01; 48(9):2610-7. PubMed ID: 2451562
    [Abstract] [Full Text] [Related]

  • 12. Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.
    Weiner LM, O'Dwyer J, Kitson J, Comis RL, Frankel AE, Bauer RJ, Konrad MS, Groves ES.
    Cancer Res; 1989 Jul 15; 49(14):4062-7. PubMed ID: 2786751
    [Abstract] [Full Text] [Related]

  • 13. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models.
    Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, Goldmacher VS, Blättler WA.
    Cancer Res; 1993 Mar 15; 53(6):1360-7. PubMed ID: 7680284
    [Abstract] [Full Text] [Related]

  • 14. Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.
    Spitler LE, del Rio M, Khentigan A, Wedel NI, Brophy NA, Miller LL, Harkonen WS, Rosendorf LL, Lee HM, Mischak RP.
    Cancer Res; 1987 Mar 15; 47(6):1717-23. PubMed ID: 3493066
    [Abstract] [Full Text] [Related]

  • 15. Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.
    Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG.
    J Clin Oncol; 2009 Sep 10; 27(26):4371-7. PubMed ID: 19636010
    [Abstract] [Full Text] [Related]

  • 16. Correlation between in vivo toxicity and preclinical in vitro parameters for the immunotoxin anti-B4-blocked ricin.
    Grossbard ML, Lambert JM, Goldmacher VS, Blättler WA, Nadler LM.
    Cancer Res; 1992 Aug 01; 52(15):4200-7. PubMed ID: 1379121
    [Abstract] [Full Text] [Related]

  • 17. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.
    Leonard JP, Coleman M, Ketas JC, Chadburn A, Furman R, Schuster MW, Feldman EJ, Ashe M, Schuster SJ, Wegener WA, Hansen HJ, Ziccardi H, Eschenberg M, Gayko U, Fields SZ, Cesano A, Goldenberg DM.
    Clin Cancer Res; 2004 Aug 15; 10(16):5327-34. PubMed ID: 15328168
    [Abstract] [Full Text] [Related]

  • 18. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
    Longo DL, Duffey PL, Gribben JG, Jaffe ES, Curti BD, Gause BL, Janik JE, Braman VM, Esseltine D, Wilson WH, Kaufman D, Wittes RE, Nadler LM, Urba WJ.
    Cancer J; 2000 Aug 15; 6(3):146-50. PubMed ID: 10882329
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
    Wawrzynczak EJ, Cumber AJ, Henry RV, May J, Newell DR, Parnell GD, Worrell NR, Forrester JA.
    Cancer Res; 1990 Dec 01; 50(23):7519-26. PubMed ID: 2253201
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.